The tumor-agnostic drug ‘Vitrakvi’ has landed in the Big 5 tertiary hospitals in Korea.

According to industry sources, Bayer Korea’s neurotrophic tyrosine receptor kinase targeted anticancer drug Vitrakvi (larotrectinib) has passed the drug committees of major hospitals in Korea, including general hospitals like the Samsung Medical Center, Seoul National University Hospital, Seoul St.Mary’s Hospital, Asan Medical Center, and Sinchon Severance Hospital and major medical institutions such as Gangnam Severance Hospital, National Cancer Center, and Seoul National University Bundang Hospital.

The drug is seemingly settling quickly in the prescription market after it was listed for reimbu